The delivery of antisense therapeutics

Advanced Drug Delivery Reviews

Volumn 44, Issue 1, 2000, Pages 3-21

  Akhtar, Saghir ^a   Hughes, Marcus D ^a,b   Khan, Alim ^a,b   Bibby, Mike ^b   Hussain, Majad ^a,b   Nawaz, Qamar ^a,b   Double, John ^b   Sayyed, Pakeeza ^a,b  

^a Pharmaceutical Sciences Institute   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Antisense; Biodegradable polymer; Brain delivery; Delivery; DNAzymes; Liposomes; Microspheres; Oral delivery; Receptor mediated; Ribozymes

Indexed keywords

BIODEGRADATION; BIOPOLYMERS; DISEASES; DNA; DRUG THERAPY;

ANTISENSE THERAPEUTICS; RIBOZYMES;

CONTROLLED DRUG DELIVERY;

ALICAFORSEN; AMPHOPHILE; ANGIOENZYME; ANGIOZYME; ANTISENSE OLIGODEOXYNUCLEOTIDE; CARRIER PROTEIN; CGP 69846A; DENDRIMER; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; HERZYME; ISIS 14803; ISIS 2503; ISIS 3521; LIPOSOME; MG 98; RECEPTOR; RIBOZYME; UNCLASSIFIED DRUG;

CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; REVIEW;

EID: 0034739601     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00080-6     Document Type: Article

References (105)

1. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:(1):1997;12-18.
2. Juliano R.L., Alahari S., Yoo H., Cho M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16:1999;494-502.
3. Kandimalla E.R., Agrawal S. Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today. 6:2000;72-81.
4. Sioud M. Application of preformed hammerhead ribozymes in gene therapy of cancer. Int. J. Mol. Med. 3:1999;381-384.
5. Sen D., Geyer C.R. DNA enzymes. Curr. Opin. Chem. Biol. 2:1998;680-687.
6. Soukup G.A., Breaker R.R. Nucleic Acid Molecular switches. TIBTECH. 17:1999;469-476.
7. Santoro S.W., Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA. 94:1997;4262-4266.
8. Akhtar S. Antisense technology: Selection and delivery of optimally acting antisense oligonucleotides. J. Drug Targeting. 5:(4):1998;225-234.
9. O'Dwyer P.J., Stevenson J.P., Gallagher M., Cassella A., Vasilevskaya I., Monia B.P., Holmlund J., Dorr F.A., Yao K.S. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 5:(12):1999;3977-3982.
10. Monia B.P., Sasmor H., Johnston J.F., Freier S.M., Lesnik E.A., Muller M., Geiger T., Altmann K.H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA. 93:(26):1996;15481-15484.
11. M. Sohail, E.M. Southern, Selecting optimal antisense reagents, Adv. Drug Deliv. Rev., (2000) in press.
12. Ho S.P., Britton D.H.O., Stone B.A., Behrens D.L., Leffet L.M., Hobbs F.W., Miller J.A., Trainor G.L. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24:(10):1996;1901-1907.
13. W.F. Lima, V. Brown-Drivers, M. Fox, R. Hanecak, T.W. Bruice, Combinatorial screening and rational optimization for hybridization to-folded hepatitis C virus RNA of oligonucleotides with biological antisense activity, J. Biol. Chem. 272(1) (1997) 626-638.
14. Scherr M., Rossi J.J. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts. Nucleic Acids Res. 26:(22):1998;5079-5085.
15. Birikh K.R., Berlin Y.A., Soreq H., Eckstein F. Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA. 3:(4):1997;429-437.
16. Southern E.M. DNA chips Analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet. 12:(3):1996;110-115.
17. Southern E.M., Casegreen S.C., Elder J.K., Johnson M., Mir K.U., Wang L., Williams J.C. Arrays Of Complementary Oligonucleotides For Analyzing the Hybridization Behavior Of Nucleic Acids. Nucleic Acids Res. 22:(8):1994;1368-1373.
18. Milner N., Mir K.U., Southern E.M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol. 15:(6):1997;537-541.
19. Wickstrom E. Oligodeoxynucleotide Stability In Subcellular Extracts and Culture Media. J. Biochem. Biophys. Methods. 13:(2):1986;97-102.
20. Akhtar S., Kole R., Juliano R.L. Stability Of Antisense DNA Oligodeoxynucleotide. Analogs In Cellular Extracts and Sera. Life Sci. 49:(24):1991;1793-1801.
21. Hudson A.J., Normand N., Ackroyd J., Akhtar S. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int. J. Pharm. 182:(1):1999;49-58.
22. Ion G. Oligonucleotide Analogs as potential chemotherapeutic - Agents. Pharmaceutical Research. 5:(9):1988;539-549.
23. Kashihara N., Maeshima Y., Makino H. Antisense oligonucleotides. Exp. Nephrol. 6:(1):1998;84-88.
24. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6:(6):1999;343-351.
25. Hamilton S.E., Simmons C.G., Kathiriya I.S., Corey D.R. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. Biol. 6:(6):1999;343-351.
26. Khatsenko O., Morgan R., Truong L., YorkDefalco C., Sasmor H., Conklin B., Geary R.S. Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length. Antisense Nucl. Acid Drug Dev. 10:(1):2000;35-44.
27. Knight D.A., Briggs B.R., Bennett C.F., Harindranath N., Waldman W.J., Sedmak D.D. Attenuation of cytomegalovirus-induced endothelial intercellular adhesion molecule-1 mRNA/protein expression and T lymphocyte adhesion by a 2′-O-methoxyethyl antisense oligonucleotide. Transplantation. 69:(3):2000;417-426.
28. Arora V., Knapp D.C., Smith B.L., Statdfield M.L., Stein D.A., Reddy M.T., Weller D.D., Iversen P.L. c-myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J. Pharm. Exp. Ther. 292:(3):2000;921-928.
29. Qin G.Z., Taylor M., Ning Y.Y., Iversen P., Kobzik L. In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-alpha. Antisense Nucl. Acid Drug Dev. 10:(1):2000;11-16.
30. Beigelman L., McSwiggen J.A., Draper K.G., Gonzalez C., Jensen K., Karpeisky A.M., Modak A.S., Matulicadamic J., Direnzo A.B., Haeberli P., Sweedler D., Tracz D., Grimm S., Wincott F.E., Thackray V.G., Usman N. Chemical Modification Of Hammerhead Ribozymes - Catalytic Activity and Nuclease Resistance. J. Biol. Chem. 270:(43):1995;25702-25708.
31. Prasmickaite L., Hogset A., Maelandsmo G., Berg K., Goodchild J., Perkins T., Fodstad O., Hovig E. Intracellular metabolism of a 2′-O-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis. Nucleic Acids Res. 26:(18):1998;4241-4248.
32. Konopka K., Rossi J.J., Swiderski P., Slepushkin V.A., Duzgunes N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta Biomembr. 1372:(1):1998;55-68.
33. Zhang X.Y., Yamada R., Shimayama T., Imada K., Uchiyama T., Hattori T. Phosphorothiolate ribozyme against the conserved sequence in V3 loop of HIV-1. Biochem. Biophys. Res. Commun. 229:(2):1996;466-471.
34. Fell P.L., Hudson A.J., Reynolds M.A., Usman N., Akhtar S. Cellular uptake properties of a 2′-amino/2′-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Antisense Nucl. Acid Drug Dev. 7:(4):1997;319-326.
35. Hertel K.J., Pardi A., Uhlenbeck O.C., Koizumi M., Ohtsuka E., Uesugi S., Cedergren R., Eckstein F., Gerlach W.L., Hodgson R., Symons R.H. Numbering System For the Hammerhead. Nucleic Acids Res. 20:(12):1992;3252.
36. Akhtar S., Juliano R.L. Cellular uptake and intracellular fate of antisense oligonucleotides. TICB. 2:1992;139-144.
37. Loke S.L., Stein C., Zhang X., Avigan M., Cohen J., Neckers L.M. Delivery Of C-Myc Antisense Phosphorothioate Oligodeoxynucleotides to Hematopoietic-Cells In Culture By Liposome Fusion - Specific Reduction In C-Myc Protein Expression Correlates With Inhibition Of Cell-Growth and DNA-synthesis. Curr. Top. Microbiol. Immunol. 141:1988;282-289.
38. Islam A., Handley S.L., Thompson K.S.J., Akhtar S. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. J. Drug Targeting. 7:(5):2000;373-382.
39. Leonetti J.P., Mechti N., Degols G., Gagnor C., Lebleu B. Intracellular-Distribution Of Microinjected Antisense Oligonucleotides. Proc. Natl. Acad. Sci. USA. 88:(7):1991;2702-2706.
40. Lukacs G.L., Haggie P., Seksek O., Lechardeur D., Freedman N., Verkman A.S. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275:(3):2000;1625-1629.
41. Hughes J., Astriab A., Yoo H., Alahari S., Liang E., Sergueev D., Shaw B.R., Juliano R.L. In vitro transport and delivery of antisense oligonucleotides. Methods Enzymol. 313:2000;342-358.
42. Tari A.M. Preparation and application of liposome-incorporated oligodeoxynucleotides. Methods Enzymol. 313:2000;372-388.
43. Roh H., Pippin J., Drebin J.A. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 60:(3):2000;560-565.
44. Abe T., Suzuki S., Hatta T., Takai K., Yokota T., Takaku H. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells. Antiviral Chem. Chemother. 9:(3):1998;253-262.
45. Alahari S.K., Dean N.M., Fisher M.H., DeLong R., Manoharan M., Tivel K.L., Juliano R.L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 50:(4):1996;808-819.
46. Kisich K.O., Malone R.W., Feldstein P.A., Erickson K.L. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment. J. Immunol. 163:(4):1999;2008-2016.
47. Gu J.L., Nadler J., Rossi J. Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle. Mol. Cell. Biochem. 172:(1-2):1997;47-57.
48. Farhood H., Bottega R., Epand R.M., Huang L. Effect Of Cationic Cholesterol Derivatives On Gene-Transfer and Protein-Kinase-C Activity. Biochim. Biophys. Acta. 1111:(2):1992;239-246.
49. Zelphati O., Szoka F.C. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:(9):1996;1367-1372.
50. Williams S.A., Buzby J.S. Cell-specific optimization of phosphorothioate antisense oligodeoxynucleotide delivery by cationic lipids. Methods Enzymol. 313:2000;388-397.
51. Takagi T., Hashiguchi M., Hiramatsu T., Yamashita F., Takakura Y., Hashida M. Effect of cationic liposomes on intracellular trafficking and efficacy of antisense oligonucleotides in mouse peritoneal macrophages. J. Drug Targeting. 7:(5):2000;363-373.
52. DeLong R.K., Yoo H., Alahari S.K., Fisher M., Short S.M., Kang S.H., Kole R., Janout V., Regan S.L., Juliano R.L. Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 27:(16):1999;3334-3341.
53. DeOliveira M.C., Fattal E., Couvreur P., Lesieur P., Bourgaux C., Ollivon M., Dubernet C. pH-Sensitive liposomes as a carrier for oligonucleotides a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochim. Biophys. Acta Biomembr. 1372:(2):1998;301-310.
54. Senior J.H. Fate and Behavior Of Liposomes Invivo - a Review Of Controlling Factors. CRC Crit. Rev. Ther. Drug Carrier Sys. 3:(2):1987;123-193.
55. Kamps J., Morselt H.W.M., Scherphof G.L. Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: In vivo-in vitro differences. Biochem. Biophys. Res. Commun. 256:(1):1999;57-62.
56. Dass C.R., Burton M.A. Lipoplexes and tumours. A review. J. Pharm. Pharmacol. 51:(7):1999;755-770.
57. Klibanov A.L., Maruyama K., Torchilin V.P., Huang L. Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time Of Liposomes. FEBS Lett. 268:(1):1990;235-237.
58. Sommer W., Cui X., Erdmann B., Wiklund L., Bricca G., Heilig M., Fuxe K. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucl. Acid Drug Dev. 8:(2):1998;75-85.
59. DeLong R., Stephenson K., Loftus T., Fisher M., Alahari S., Nolting A., Juliano R.L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:(6):1997;762-764.
60. Bielinska A., KukowskaLatallo J.F., Johnson J., Tomalia D.A., Baker J.R. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:(11):1996;2176-2182.
61. Haensler J., Szoka F.C. Polyamidoamine Cascade Polymers Mediate Efficient Transfection Of Cells In Culture. Bioconj. Chem. 4:(5):1993;372-379.
62. Poxon S.W., Mitchel P.M., Liang E., Hughes J.A. Dendrimer delivery of oligonucleotides. Drug Deliv. 3:1996;255-261.
63. Skalko N., Peschka R., Altenschmidt U., Lung A., Schubert R. pH-sensitive liposomes for receptor-mediated delivery to chicken hepatoma (LMH) cells. FEBS Lett. 434:(3):1998;351-356.
64. Biessen E.A.L., Vietsch H., Rump E.T., Fluiter K., Kuiper J., Bijsterbosch M.K., VanBerkel T.J.C. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem. J. 340:(3):1999;783-792.
65. Kren B.T., Metz R., Kumar R., Steer C.J. Gene repair using chimeric RNA DNA oligonucleotides. Semin. Liver Dis. 19:(1):1999;93-104.
66. Rojanasakul Y., Weissman D.N., Shi X.L., Castranova V., Ma J.K.H., Liang W.W. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J. Biol. Chem. 272:(7):1997;3910-3914.
67. Chaudhuri G. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages - Selective and efficient elimination of the parasite. Biochem. Pharmacol. 53:(3):1997;385-391.
68. Schwarze S.R., Dowdy S.F. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21:(2):2000;45-48.
69. Dokka S., Toledo-Velasquez D., Shi X.L., Wang L.Y., Rojanasakul Y. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm. Res. 14:(12):1997;1759-1764.
70. Morris M.C., Vidal P., Chaloin L., Heitz F., Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25:(14):1997;2730-2736.
71. Schwarze S.R., Ho A., VoceroAkbani A., Dowdy S.F. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science. 285:(5433):1999;1569-1572.
72. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. Transferrin Receptor On Endothelium Of Brain Capillaries. Nature. 312:(5990):1984;162-163.
73. 125] Transferrin Through the Rat Blood-Brain Barrier. Brain Res. 683:(2):1995;164-171.
74. Boado R.J., Pardridge W.M. Complete Inactivation Of Target Messenger-RNA By Biotinylated Antisense Oligodeoxynucleotide-Avidin. Conj. Bioconj. Chem. 5:(5):1994;406-410.
75. Boado R.J., Kang Y.S., Wu D.F., Pardridge W.M. Rapid Plasma-Clearance and Metabolism In-Vivo Of a Phosphorothioate Oligodeoxynucleotide With a Single Internal Phosphodiester Bond. Drug. Metab. Dispos. 23:(11):1995;1297-1300.
76. N. Normand-Sdiqui, S. Akhtar, Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX-26) conjugates into an in vitro immortalised cell line model of the blood-brain barrier, Int. J. Pharm. 163(1-2) (1998) 63-71.
77. Wu D.F., Boado R.J., Pardridge W.M. Pharmacokinetics and blood-brain barrier transport of [H-3]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharm. Exp. Ther. 276:(1):1996;206-211.
78. Kathmann M., Bauer U., Schlicker E. CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide. Naunyn-Schmiedebergs Arch. Pharmacol. 360:(4):1999;421-427.
79. Tremblay M., Rouillard C., Levesque D. Dopamine D-3 receptor antisense administration reduces basal c-fos and NGFI-B mRNA levels in the rat forebrain. Synapse. 32:(1):1999;51-57.
80. LeCorre S.M., Burnet P.W.J., Meller R., Sharp T., Harrison P.J. Critical issues in the antisense inhibition of brain gene expression in vivo: Experiences targeting the 5-HT1A receptor. Neurochem. Int. 31:(3):1997;349-362.
81. A. Khan, W. Sommer, K. Fuxe, S. Akhtar, Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain, J. Drug Target., in press.
82. Agrawal S., Zhao Q.Y. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:(4):1998;519-528.
83. Lewis K.J., Irwin W.J., Akhtar S. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: Characterization of P(LA-GA) copolymer microspheres in vitro. J. Drug Targeting. 5:(4):1998;291-302.
84. Putney S.D., Brown J., Cucco C., Lee R., Skorski T., Leonetti C., Geiser T., Calabretta B., Zupi G., Zon G. Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. Antisense Nucl. Acid Drug Dev. 9:(5):1999;451-458.
85. Cleek R.L., Ting K.C., Eskin S.G., Mikos A.G. Microparticles of poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery. J. Control. Rel. 48:(2-3):1997;259-268.
86. Hudson A.J., Lewis K.J., Rao M.V., Akhtar S. Biodegradable polymer matrices for the sustained exogenous delivery of a biologically active c-myc hammerhead ribozyme. Int. J. Pharm. 136:(1-2):1996;23-29.
87. Lewis K.J., Irwin W.J., Akhtar S. Biodegradable Poly(L-Lactic Acid) Matrices For the Sustained Delivery Of Antisense Oligonucleotides. J. Control. Rel. 37:(1-2):1995;173-183.
88. Akhtar S., Lewis K.J. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int. J. Pharm. 151:(1):1997;57-67.
89. Chavany C., Ledoan T., Couvreur P., Puisieux F., Helene C. Polyalkylcyanoacrylate Nanoparticles As Polymeric Carriers For Antisense Oligonucleotides. Pharm. Res. 9:(4):1992;441-449.
90. Chavany C., Saisonbehmoaras T., Ledoan T., Puisieux F., Couvreur P., Helene C. Adsorption Of Oligonucleotides Onto Polyisohexylcyanoacrylate Nanoparticles Protects Them Against Nucleases and Increases Their Cellular Uptake. Pharm. Res. 11:(9):1994;1370-1378.
91. Fattal E., Vauthier C., Aynie I., Nakada Y., Lambert G., Malvy C., Couvreur P. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Rel. 53:(1-3):1998;137-143.
92. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saisonbehmoaras T. Antisense Oligonucleotides Adsorbed to Polyalkylcyanoacrylate Nanoparticles Specifically Inhibit Mutated Ha-Ras-Mediated Cell-Proliferation and Tumorigenicity In Nude-Mice. Proc. Natl. Acad. Sci. USA. 91:(22):1994;10460-10464.
93. Vlassov V.V., Karamyshev V.N., Yakubov L.A. Penetration Of Oligonucleotides Into Mouse Organism Through Mucosa and Skin. FEBS Lett. 327:(3):1993;271-274.
94. Agrawal S., Zhang X.S., Lu Z.H., Zhao H., Tamburin J.M., Yan Y.M., Cai H.Y., Diasio R.B., Habus I., Jiang Z.W., Iyer R.P., Yu D., Zhang R.W. Absorption, Tissue Distribution and In-Vivo Stability In Rats Of a Hybrid Antisense Oligonucleotide Following Oral-Administration. Biochem. Pharmacol. 50:(4):1995;571-576.
95. Wang H., Cai Q.Y., Zeng X.F., Yu D., Agrawal S., Zhang R.W. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RI alpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA. 96:(24):1999;13989-13994.
96. Nicklin P.L., Bayley D., Giddings J., Craig S.J., Cummins L.L., Hastewell J.G., Phillips J.A. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes. Pharm. Res. 15:(4):1998;583-591.
97. Hughes J.A., Avrutskaya A.V., Brouwer K.L.R., Wickstrom E., Juliano R.L. Radiolabeling Of Methylphosphonate and Phosphorothioate Oligonucleotides and Evaluation Of Their Transport In Everted Rat Jejunum Sacs. Pharm. Res. 12:(6):1995;817-824.
98. Beck G.F., Irwin W.J., Nicklin P.L., Akhtar S. Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial Caco-2 cells. Pharm. Res. 13:(7):1996;1028-1037.
99. Akhtar S., Beck G.F., Hawley P., Irwin W.J., Gibson I. The influence of polarized epithelial (Caco-2) cell differentiation on the cellular binding of phosphodiester and phosphorothioate oligonucleotides. Antisense Nucl. Acid Drug Dev. 6:(3):1996;197-206.
100. Moore V.A., Dunnion D.J., Brown T., Irwin W.J., Akhtar S. Interaction of oligonucleotide-conjugates with the dipeptide transporter system in caco-2 cells. Biochem. Pharmacol. 53:(9):1997;1223-1228.
101. Flory C.M., Pavco P.A., Jarvis T.C., Lesch M.E., Wincott F.E., Beigelman L., Hunt S.W., Schrier D.J. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Natl. Acad. Sci. USA. 86:1996;6454-6458.
102. Lyngstadaas S.P., Risnes S., Sproat B.S., Thrane P.S., Prydz H.P. A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. 14:1995;5224-5229.
103. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor-activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nature Med. 2:1996;668-675.
104. Yazaki T., Ahmad S., Chahlavi A., Zylberkatz E., Dean N.M., Rabkin S.D., Martuza R.L., Glazer R.I. Treatment Of Glioblastoma U-87 By Systemic Administration Of An Antisense Protein-Kinase C-Alpha Phosphorothioate Oligodeoxynucleotide. Mol. Pharmacol. 50:1996;236-242.
105. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction Of Nk Activity In Murine And Human-Cells By CPG Motifs In Oligodeoxynucleotides And Bacterial-DNA. J. Immunol. 157:1996;1840-1845.